SEC.gov | SEC Charges Cassava Sciences, Two Former Executives …
WEB5 days ago · The Securities and Exchange Commission today announced Cassava Sciences, Inc., its founder and former CEO, Remi Barbier, and its former Senior Vice President of Neuroscience, Dr. Lindsay Burns, will pay more than $40 million to settle charges related to misleading statements made in September 2020 about the results of a Phase 2 clinical trial for the company’s purported therapeutic for the ...
Cassava Sciences Resolves SEC Investigation
WEB5 days ago · AUSTIN, Texas, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (“Cassava” or the “Company”) (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today announced that it has reached a settlement with the U.S. Securities and Exchange Commission (“SEC”) of negligence-based disclosure charges that resolve a previously-disclosed SEC investigation into ...
SEC charges Cassava over 'misleading' Alzheimer's claims
WEB1 day ago · Cassava will pay $40 million to settle the civil charges, while Barbier and Burns, have agreed to pay $175,000 and $85,000, respectively. Wang will pay a $50,000 penalty. "Cassava claimed that the ...
SEC Charges Cassava Sciences Over Manipulated Alzheimer's Trial …
WEB4 days ago · Alzheimer’s drug developer Cassava Sciences Inc (NASDAQ:SAVA), its founder Remi Barbier, and former Senior VP of Neuroscience Lindsay Burns have agreed to pay over $40 million to resolve SEC ...
Company misled investors on possible Alzheimer’s drug, SEC …
WEB22 hours ago · The troubled biopharma company Cassava Sciences agreed last week to pay $40 million to settle U.S. Securities and Exchange Commission (SEC) charges that it had misled investors about early clinical results for its experimental Alzheimer’s disease drug, simufilam. The compound is now in pivotal phase 3 …
Cassava Sciences Resolves SEC Investigation - Yahoo Finance
WEB4 days ago · Advertisement. AUSTIN, Texas, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (“Cassava” or the “Company”) (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s ...
Cassava Sciences, Inc., Remi Barbier, and Lindsay Burns - SEC.gov
WEB5 days ago · Cassava Sciences, Inc., Remi Barbier, and Lindsay Burns, No. 1:24-cv-01150 ... The SEC’s complaint alleges that Cassava and Burns misled investors with claims that its Phase 2 trial was conducted in blinded conditions, even though the scientist testing the samples – who was also the co-inventor of the therapeutic – had been unblinded. ...
Cassava to Pay $40 Million to SEC Over Alzheimer’s Drug Claims
WEB4 days ago · Drugmaker Cassava Sciences Inc. and two former executives agreed to pay more than $40 million to resolve US Securities and Exchange Commission claims they misled the public about the success of an Alzheimer’s drug trial.. Cassava published results in 2020 based on hand-selected data that showed patients’ memories improved, though the full data showed no measurable progress, the SEC said in ...
Cassava Sciences Resolves SEC Investigation - GlobeNewswire
WEB4 days ago · Cassava Sciences Resolves SEC Investigation. AUSTIN, Texas, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (“Cassava” or the “Company”) (Nasdaq: SAVA), a biotechnology company ...
SEC Charges Cassava Sciences, Former Executives for
WEB5 days ago · Cassava, Barbier, and Burns also agreed to pay civil penalties of $40 million, $175,000, and $85,000, respectively, the SEC said. The two former executives also agreed to be subject to officer-and ...
- Some results have been removed